@misc{10481/97885,
year = {2024},
month = {12},
url = {https://hdl.handle.net/10481/97885},
abstract = {The increase in age-related comorbidities, such as cardiometabolic diseases, has become a global health priority. There
is a growing need to find new parameters capable of improving the detection of cardiometabolic risk factors, and circulating
endocannabinoids (eCBs) are a promising tool in this context. Here, we aimed to investigate the relationship
between plasma levels of eCBs and their analogues with body composition and cardiometabolic risk factors in middleaged
adults. Seventy-two individuals (54% women; 53.6 ± 5.1 years old) were included in this study. Plasma levels of
eCBs and analogues were determined using liquid chromatography-tandem mass spectrometry. Body composition was
measured by dual-energy X-ray absorptiometry. Cardiometabolic risk factors (i.e., glucose and lipid profile, blood pressure,
liver and renal parameters, and gonadal hormones) were also assessed. The plasma levels of 1- and 2-arachidonylglycerol
(1-AG&2-AG) were positively correlated with adiposity (all r ≥ 0.23, P < 0.05). Interestingly, the plasma levels
of 1-AG&2-AG, arachidonoylethanolamide, and palmitoyl-ethanolamide were positively correlated with the homeostatic
model assessment index – Insulin Resistance (HOMA-IR) (all r ≥ 0.32, P < 0.01). Our results also showed that high levels
of 1-AG&2-AG, arachidonoylethanolamide, linoleoyl ethanolamide, and palmitoleoyl ethanolamide were correlated
with poorer liver (all r ≥ 0.27, P < 0.05), kidney (all r ≥ 0.24, P < 0.05), and gonadal function parameters (testosterone: all
r > 0.26, P < 0.05, SHBG: 1-AG&2-AG r=-0.33, P < 0.01). The plasma levels of some eCBs and analogues are correlated
with a worse cardiometabolic profile in middle-aged adults.},
organization = {Spanish Ministry of Education
(FPU18/03357, and PID2022-141442OA-I00)},
organization = {Redes Temáticas
de Investigación Cooperativa RETIC (Red SAMID RD16/0022)},
organization = {University of Granada Plan Propio de Investigación 2016 -Excellence
actions: Unit of Excellence on Exercise and Health (UCEES),
the Junta de Andalucía, Consejería de Conocimiento, Investigación y Universidades (ERDF; ref. SOMM17/6107/UGR and DOC 01151)},
organization = {Texas A&M AgriLife},
organization = {University of Granada Plan Propio de Investigacion (Programa Perfeccionamiento
Doctores)},
organization = {Sara Borrell contract
(CD23/00231) from the MCIN/ ISCIII},
organization = {MCIN/AEI/ 10.13039/501100011033 and, as appropriate,
by “ESF Investing in your future”, by EASO-New Clinical Investigator
Award 2024 and by the EFSD-Rising Star 2024},
publisher = {Springer Nature},
keywords = {Cardiometabolic risk factors},
keywords = {Endocannabinoid system},
keywords = {Insulin resistance},
title = {Higher plasma levels of endocannabinoids and analogues are correlated with a worse cardiometabolic profile in middle-aged adults},
doi = {10.1007/s13105-024-01063-6},
author = {Rodríguez García, Carmen and Osuna Prieto, Francisco Javier and Kohler, Isabelle and Sánchez Gómez, Joaquín and Ruíz Campos, Samuel and Castillo, Manuel J. and Amaro Gahete, Francisco José and Martínez Téllez, Borja Manuel and Jurado Fasoli, Lucas},
}